key: cord-0883193-lt7dp4wt authors: Kruip, Marieke J. H. A.; Cannegieter, Suzanne C.; ten Cate, Hugo; van Gorp, Eric C. M.; Juffermans, Nicole P.; Klok, Frederikus A.; Maas, Coen; Vonk‐Noordegraaf, Anton title: Caging the dragon: Research approach to COVID‐19–related thrombosis date: 2021-03-08 journal: Res Pract Thromb Haemost DOI: 10.1002/rth2.12470 sha: fcafc13e4658d22cc5ba419eaf174a58cebfa5f0 doc_id: 883193 cord_uid: lt7dp4wt The incidence of venous thrombosis, mostly pulmonary embolism (PE), ranging from local immunothrombosis to central emboli, but also deep vein thrombosis (DVT) in people with coronavirus disease 2019 (COVID‐19) is reported to be remarkably high. The relevance of better understanding, predicting, treating, and preventing COVID‐19–associated venous thrombosis meets broad support, as can be concluded from the high number of research, review, and guideline papers that have been published on this topic. The Dutch COVID & Thrombosis Coalition (DCTC) is a multidisciplinary team involving a large number of Dutch experts in the broad area of venous thrombosis and hemostasis research, combined with experts on virology, critically ill patients, pulmonary diseases, and community medicine, across all university hospitals and many community hospitals in the Netherlands. Within the consortium, clinical data of at least 5000 admitted COVID‐19–infected individuals are available, including substantial collections of biobanked materials in an estimated 3000 people. In addition to considerable experience in preclinical and clinical thrombosis research, the consortium embeds virology‐hemostasis research models within unique biosafety facilities to address fundamental questions on the interaction of virus with epithelial and vascular cells, in relation to the coagulation and inflammatory system. The DCTC has initiated a comprehensive research program to answer many of the current questions on the pathophysiology and best anticoagulant treatment of COVID‐19–associated thrombotic complications. The research program was funded by grants of the Netherlands Thrombosis Foundation and the Netherlands Organization for Health Research and Development. Here, we summarize the design and main aims of the research program. The incidence of venous thromboembolic events (VTE), mostly pulmonary embolism (PE) but also deep vein thrombosis (DVT) in people with COVID-19 has been reported to be remarkably high. The first studies report VTE in up to 48% of people with COVID-19 admitted to intensive care units (ICUs) and up to 10% on hospital wards, although the reported incidences range widely because of differences in patient selection and threshold for diagnostic testing. [1] [2] [3] [4] [5] [6] [7] [8] [9] This may be higher than in other viral infections and critically ill patients with acute respiratory distress syndrome. 4, 10 Furthermore, VTE in people with COVID-19 may occur despite thromboprophylaxis with a standard dose of low-molecular-weight heparin (LMWH), suggesting a profound procoagulant state. [1] [2] [3] [4] [5] [6] [7] 11, 12 In people with COVID-19, VTE is hypothesized to be part of a systemic coagulopathy that occurs locally in the pulmonary circulation, at least in those with severe infection, referred to as "immunothrombosis." This phenomenon suggests a strong link between excessive inflammation and immunothrombosis that may not be adequately prevented or counteracted with standard anticoagulation alone. [13] [14] [15] [16] [17] [18] Although the etiology of COVID-19-associated VTE is unknown, several mechanisms have been suggested. 15, 16, 19, 20 Presumably, prothrombotic triggers include a massive immune response, involving recruitment of inflammatory cells, release of proinflammatory chemokines (in severe cases a "cytokine storm") and expression of microvascular tissue factor. A thromboinflammatory condition is suggested to occur, aggravated by platelet-leukocyte interaction, activation of the contact system, and potentially by neutrophil extracellular trap production (NETosis). 21, 22 Bradykinin and kallikrein generated in this process amplify the intrinsic coagulation. Subsequently, massive endothelial cell activation and inflammation, accompanied by high plasma levels of coagulation factors, further provides a substrate for firm clots. However, it is completely unknown if all of these suggested mechanisms are operational, in what sequence they occur, and which triggers are most important for clot formation and occurrence of VTE. The occurrence of microthrombi in the pulmonary vascular bed is suggested to be a significant part of COVID-19 pathogenesis: the remarkably high d-dimer levels in COVID-19 may relate to specific mechanisms by which the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) invades the body. [13] [14] [15] [16] It is currently unknown whether the hypercoagulable state in people with is driven by the systemic or local effect of the host immune response to infection or by direct infection of endothelial cells. SARS-CoV-2-induced thrombosis can be the result of activation of endothelial cells by circulating activated monocytes, while induction of microthrombi in the pulmonary vascular bed is due to infection of respiratory epithelial cells, which activate endothelial cells of the respiratory tract. Insight in the mechanisms resulting in the procoagulant state is necessary to substantiate therapeutic intervention and monitoring. Notably, influenza virus infections have also been shown to be associated with high incidences of thrombotic complications. [23] [24] [25] It remains to be proven that the high incidence of VTE in COVID-19 is truly a COVID-19-specific complication. In addition to short-term morbidity and mortality due to impaired gas exchange, thrombotic complications may aggravate the chronic complications of COVID-19. In the general (non-COVID) population, the post-PE syndrome and postthrombotic syndrome (PTS) have been reported to occur in 50% of people with VTE despite adequate anticoagulation therapy. 26, 27 These long-term complications have a major impact on quality of life and are associated with higher risks of depression, unemployment, social isolation, and cells, in relation to the coagulation and inflammatory system. The DCTC has initiated a comprehensive research program to answer many of the current questions on the pathophysiology and best anticoagulant treatment of COVID-19-associated thrombotic complications. The research program was funded by grants of the Netherlands Thrombosis Foundation and the Netherlands Organization for Health Research and Development. Here, we summarize the design and main aims of the research program. anticoagulants, COVID-19, pulmonary embolism, severe acute respiratory syndrome coronavirus 2, thrombosis, venous thrombosis excess health care costs. [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] However, the long-term outcomes of COVID-19-associated VTE are currently unknown. To find the best possible management of the procoagulant state of people with COVID-19, that is, to prevent and to optimally treat thrombotic complications, there is a pivotal need to better understand its pathogenesis, natural course, and risk factors. Precise knowledge of the safety and efficacy of currently prescribed thromboprophylaxis and treatments of thrombosis is necessary to guide optimal pharmacological prevention and treatment of COVID-19associated VTE. The Dutch COVID & Thrombosis Coalition (DCTC) is a multidisciplinary team involving a large number of Dutch experts in the broad area of thrombosis and hemostasis research, combined with experts on virology, critical care medicine, pulmonary diseases, and community medicine, across all university hospitals and many community hospitals in the Netherlands. Within the consortium, clinical data of at least 5000 admitted COVID-19-infected people are available, including substantial collections of biobanked materials in an estimated 3000 patients. These samples were prospectively collected from the beginning of the outbreak on, in different health care settings. Due to the emerging outbreak situation, samples were collected as part of ongoing research and biobanked in the participating institutions. Due to the emergency, there was not an overarching SARS-CoV-2 study protocol at that time. The use of biomaterial for the specific study questions on SARS-CoV-2 as described in this article was approved by the relevant local medical ethical committees. In addition to considerable experience in preclinical and clinical thrombosis research, the consortium embeds virology-hemostasis research models within unique biosafety facilities to address fundamental questions on the interaction of virus with epithelial and vascular cells, in relation to the coagulation and inflammatory system. The DCTC has initiated a comprehensive research program to answer many of the current questions on the pathophysiology and best treatment of COVID-19-associated thrombotic complications. The main objective of DCTC's research is to understand and prevent VTE in people with COVID-19, and to optimize acute treatment and long-term health of people with COVID-19 who are diagnosed with VTE. This objective concerns the overall Dutch population but also important subgroups, including age categories, sex, and ethnic groups. The subobjectives of the five involved work packages (WPs) are summarized in Table 1 , and the integration of the WPs is illustrated in Figure 1 Main objective: to unravel pathophysiological mechanisms that cause COVID-19-associated coagulopathy. 1. Investigate the presence of prothrombotic autoantibodies. 2. Investigate the status of the fibrinolytic system. 3. Evaluate the balance of the coagulation system. 4. Analyze the composition of thrombi in tissues specimens. 5. Identify molecular players and biomarkers for thrombosis. Main objective: to identify the molecular mechanisms of SARS-CoV-2-induced thrombosis using in vitro infection models of the pulmonary vascular bed. Tropism of SARS-CoV-2-infected endothelial cells will be compared to other respiratory viruses that cause VTE. 1. Determine the role of respiratory epithelial cells in inducing a procoagulant state in pulmonary microvascular endothelial cells. 2. Determine the role of activated monocytes from patients with COVID-19 in inducing a procoagulant state in endothelial cells. 3. Correlate data from in vitro experiments to pathology observations in autopsies. 4. Determine the possible effect of nonneutralizing antibodies on SARS-CoV-2 infection kinetics and dynamics in respiratory endothelial cells, epithelial cells, and monocytes. Main objective: to define the optimal strategies for prevention and treatment of VTE in patients with COVID-19. Main objective: to assess the impact and long-term consequences of VTE in patients with COVID-19. 1. Evaluate the incidence of COVID-19 associated VTE after hospital discharge. 2. Assess patient-reported outcome measures and pulmonary and cardiac function. 3. Establish the rate of thrombus resolution and the incidence of post-VTE syndromes. COVID-19, coronavirus disease 2019; ICU, intensive care unit; LMWH, low-molecular-weight heparin; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; VTE, venous thromboembolism; WP, work package. Organization for Health Research and Development. The goal of the paper is to present our aims and study design and invite other research consortia to collaborate with us in our pursuit to solve the major issue of COVID-19-associated thrombosis. In particular, we hope to connect the research in WP1 and WP2 to international studies on the specific interaction of viruses and the inflammatory and coagulation system. For WP3 and WP4, we aim to externally validate constructed models and identified associations. Increasing the number of people with COVID-19 associated VTE who were dedicatedly followed for the occurrence of long-term complications will help to accurately estimate the incidence of chronic thromboembolic pulmonary hypertension (CTEPH) and PTS (WP5). This WP has the overarching aim to obtain mechanistic insight in COVID-19-associated thrombosis. Five focus areas have been selected: (i) antiphospholipid antibodies, (ii) fibrinolysis, (iii) coagulation and anticoagulants, (iv) thrombus composition, and (5) The presence of antiphosholipid antibodies and lupus anticoagulans (LAC) has been described in people with COVID-19 and linked to unfavorable outcomes. 22 We will investigate whether the LAC phenomenon in people with COVID-19 is caused by (auto)antibodies, through heat-inactivation of LAC-positive plasma samples from COVID-19 patients. We will subsequently focus on the identification of the causal antibody population using solid-phase binding assays with immobilized phospholipids and phospholipid-binding proteins, including β2-glycoprotein I and prothrombin, the known antigens for LAC-inducing autoantibodies. To investigate the link between LAC and SARS-CoV-2 infections, we will examine cross-reactivity with SARS-CoV-2 capsid proteins and study plasma levels of autoantibody targets. We will evaluate their effects on coagulation using adapted calibrated automated thrombography, with special attention to resistance to activated protein C, as well on platelet activation. The working hypothesis is that a deregulated fibrinolytic system contributes to VTE in people with COVID-19. We will estimate plasma fibrinolytic potential using a clot lysis assay: This functional assay is sensitive for all plasma components known to be involved in clot breakdown. 36 In brief, the clot lysis assay determines the lysis of a tissue factor-induced clot (generated from 50 μL of patient plasma in 96-well microtiter plates) by exogenous tissue-type plasminogen activator by monitoring changes in turbidity during clot formation and subsequent lysis. Large epidemiological studies have shown a decreased fibrinolytic capacity assessed with this assay to strongly predict thrombotic risk. 37 In addition, strongly decreased fibrinolytic F I G U R E 1 Integration of the five work packages potential has been demonstrated to predict multiorgan failure and outcome in patients admitted to the ICU with and without underlying liver disease. 38 A hypofibrinolytic state is strongly related to plasma levels of plasminogen activator inhibitor type 1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI). 36 We therefore will assess plasma levels of both proteins. Interestingly, PAI-1 and TAFI levels increase in obesity (which is common in critically ill people with and have both been suggested to be drivers of progression of organ failure in severe infection. We will therefore assess whether PAI-1 and TAFI levels are independent predictors of adverse outcome of COVID-19 pneumonia. Hemostasis is a delicately regulated biological system. We will assess the relative contribution of the extrinsic and intrinsic pathways of coagulation and the balance between the pro-and anticoagulant pathways. 39, 40 This aim will be addressed employing a staggered approach from global overall coagulation assays to more specific assessment of individual activation markers of coagulation. Specifically designed thrombin generation assays will be applied to determine the extent of hypercoagulability and the contribution of the protein C pathway (activated protein C sensitivity ratio [APCsr], thrombomodulin). Quantification of coagulation proteases including enzyme-inhibitor complexes will allow for detailed insight into the pathways involved. Due to potential limitations in sample transport, all assays will be optimized for use in each participating institute with shared standardized operating procedures. Autopsies of people with COVID-19 are, and will be, performed at the Leiden and Rotterdam medical centers. In the thrombi tissue specimens achieved during autopsy, we will investigate thrombus structure and composition in relation to plasma biomarkers associated with thrombosis and formation neutrophil extracellular traps, age, sex, medication, duration and severity of SARS-CoV-2, and investigate if thrombus architecture predicts the early outcome of disease in people with COVID-19. The biobank of samples in the participating centers includes collected thrombi and plasma that are available for this study, in which we will expand on the thrombus analysis. The composition of the collected thrombi and of in vitro plasma clots will be characterized using state-of-the-art imaging techniques, such as scanning electron microscopy (SEM), routine immunocytochemistry, and advanced fluorescence superresolution confocal microscopy. Thrombus histology will focus on fibrin structure and (inflammatory) cellular composition. Specific immunohistological stainings for fibrin, neutrophils, and markers of NETosis will help in understanding the pathophysiology of thrombosis in people with COVID-19 and may be extended, with more in-depth approaches such as RNA sequencing. The structural characteristics of fibrin fibers that determine permeability will be analyzed by SEM. These analyses will be compared to functional analyses of fibrinolysis rates (ie, the time that is required to degrade the fibrin matrix in vitro). These characteristics are determined by the structural properties of the matrix and by the adherence of cells and proteins during clot formation. For the longitudinal analysis of internal thrombus heterogeneity, sections will be obtained serially, which allows for three-dimensional reconstruction. In these sections, we will determine the amount and characteristics of the fibrin matrix, DNA extracellular traps, the number and type of cells and bound proteins, and their location within the thrombus by immunocytochemistry and proteomics. Findings will be linked to the data of patients with COVID-19 to also consider a relationship with other data available from the case (including clinical data and blood and plasma values). We will use proteomic and genetic analyses to identify molecular players and possible biomarkers for thrombosis in COVID-19. Recently, an automated, robust, and reproducible workflow for plasma profiling was implemented. 41 This technology provides a "hemostatic and inflammatory signature" by quantifying hundreds of plasma proteins simultaneously, including plasma proteins related to the coagulation and complement system. Importantly, this technology also allows for the detection of releasable contents of platelets, neutrophils, and endothelial cells that are intrinsically linked to thromboinflammatory events. To study the underlying pathogenesis of VTE in people with COVID-19, we will apply RNA-sequencing autopsy material (specifically from the lungs) from deceased people with COVID-19. Lung material from non-COVID patients will be used as a control. RNA sequencing from formalin-fixed paraffin-embedded material is very feasible using protocols from the Pathology Department at LUMC. Gene signatures (top 200 upregulated and downregulated genes compared to controls) will be analyzed with online prediction tools such as Ingenuity Pathway Analysis and Enrichr to determine biologically relevant pathways underlying COVID-19-associated thrombotic events, as done before for cancer-associated thrombotic events. 42 We expect genes and biological pathways associated with inflammation, complement and platelet activation, contact activation, and the intrinsic coagulation pathway to be upregulated. The main objective in this WP is to identify the molecular mecha- The postulation that activated monocytes in people with COVID-19 induce a procoagulant state in endothelial cells will be investigated. We will analyze monocytes from people with COVID-19 on tissue factor activity. Furthermore, these monocytes will be cocultured with The key aims of WP3 are ( of centers and related to type and dose of anticoagulant as well as to clinical outcomes. More centers will be engaged to include such assays or, if not available on site, to store plasma samples for analysis. Currently, the observed high risk of thrombotic complications in admitted patients with COVID-19 leads to strong preventive measures, that is, administering of double or even therapeutic dosages of LMWH in ICU patients. A high dose of thromboprophylaxis may be effective to prevent thrombosis in patients with a high risk of thrombosis, but it will also needlessly increase the bleeding risk. It is therefore of utmost clinical importance to identify subjects at particular low or high thrombosis risk, to expose only high-risk individuals to the benefits and risks of thromboprophylaxis. centers, some data may be missing. As we consider these data to be missing at random, we will use multiple imputation techniques. The association between candidate predictors and VTE will be assessed by Fine-Gray regression analyses using backward selection procedures (criterion P < .15), applying a time scale starting at hospital admission, and adjusting for competing risk of death. 49 Continuous predictors will not be categorized, and splines will be used to model possible nonlinear relations. The magnitude of discrimination of the model will be quantified with Harrell's C-statistic. Regression coefficients will be reduced using a cross-validated penalized regression approach to correct for optimism. 50 Subgroup analyses will be performed using different subsets of predictors and of outcome phenotypes, first according to the different mechanistic pathways as mentioned under WP1 and WP2. Second, separate models will be developed and compared for the different VTE phenotypes (characterized as detailed as possible based on clinical and radiological information) as well as separate models limited to ICU patients and starting follow-up from the day of ICU admission. Internal validation will be taken into account by use of cross-validated penalized regression. For external validation, we plan to use data from international collaborators. A dedicated patient pathway ( Figure 2 ) will be established in all participating hospitals in close collaboration between the departments of pulmonology, internal/vascular medicine, hematology, and cardiology, where all previously admitted patients with COVID-19 will be followed. At the 3-month follow-up visit, all survivors with objective VTE diagnosed will be identified and subjected to state-of-the-art follow-up procedures as recommended by current Dutch guidelines, aimed at establishing the rate of thrombus resolution and early identification and treatment of long-term VTE consequences, at efficient use of health care resources. After both 3-month and 12-month follow-up, the recovery of patients will be assessed using patient-reported outcome measures of quality of life, dyspnea, and functional status. 28, [51] [52] [53] Dedicated diagnostic tests will be applied where appropriate to investigate new or persistent unexplained symptoms or poor functional recovery. 54 In addition to the standard follow-up procedures applied to all COVID-19 survivors, the presence of and risk factors for CTEPH will be assessed in all patients. The pretest probability of CTEPH will be estimated by calculating the "CTEPH prediction score." [55] [56] [57] Only patients with a high pretest probability (>6 points) or those with symptoms that might be associated with CTEPH will be subjected to the CTEPH rule-out criteria, that is, assessment of the presence of any of the three electrocardiographic criteria of right ventricular (RV) pressure overload, or an abnormal age-and gender-dependent N-terminal prohormone of brain natriuretic peptide level. [57] [58] [59] of life, and parameters of physical performance will be assessed. At the 1-year follow-up visit, patients with persistent symptoms of dyspnea or decreased functional status will be subjected to appropriate diagnostic tests to rule out the presence of late-onset CTEPH. At 6 months, repeat ultrasound imaging of the affected leg will be routinely performed to evaluate the presence and extend of persistent vein obstruction, and the presence of PTS will be established using the Villalta score. 27, 63 Compression therapy will be tailored on the basis of clinical signs and symptoms scored according to the Villalta PTS scale; patients assigned to individualized therapy with two consecutive Villalta scores of ≤4 will be counseled to stop using the stockings. 64, 65 All patients will be followed for 1 year for evaluation of the course of PTS symptoms. The proposed project is challenging. Mainly, the success of the WPs depends on the actual availability and quality of the biobanks that were built, the possibility to extend and merge large existing databases in the participating hospitals, the strict and independent adjudication of all relevant study outcomes, and the number of patients on whom data (during both admission and long-term follow-up) are available for analysis. Much also will depend on the intensity of second or more waves of infection, which will increase the available data/ material to work with but also limit the availability of the clinicians to be involved in clinical studies and the possibility to perform preclinical experiments. The proposed outcome from in vivo and in vitro experiments will give us further insights necessary to understand the pathophysiology of thrombotic complications in people with COVID-19, and the clinical studies will help predict thrombotic complications as well as optimize therapeutic and preventive strategies. Finally, by focused and rigorous follow-up of patients with COVID-19, long-term complications will be identified early, which will allow for optimal long-and shortterm treatment of these patients. The research program was funded by grants of the Netherlands Incidence of thrombotic complications in critically ill ICU patients with COVID-19 Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: an updated analysis Incidence of venous thromboembolism in hospitalized patients with COVID-19 High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study Incidence of deep vein thrombosis among non-ICU patients hospitalized for COVID-19 despite pharmacological thromboprophylaxis Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19) Venous thromboembolism in critically Ill patients with COVID-19: results of a screening study for deep vein thrombosis Risk of venous thromboembolism in patients with COVID-19: a systematic review and meta-analysis. Res Pract Thrombosis Haemostasis Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review Pulmonary embolism or pulmonary thrombosis in COVID-19? Is the recommendation to use high-dose heparin for thromboprophylaxis justified? Clinical and computed tomography characteristics of COVID-19 associated acute pulmonary embolism: a different phenotype of thrombotic disease? Pathological findings of COVID-19 associated with acute respiratory distress syndrome Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19 Thromboinflammation and the hypercoagulability of COVID-19 Thrombosis and coagulopathy in COVID-19: an illustrated review COVID-19 associated coagulopathy and thromboembolic disease: commentary on an interim expert guidance SARS-CoV-2 and viral sepsis: observations and hypotheses Hypercoagulability of COVID-19 patients in intensive care unit: a report of thromboelastography findings and other parameters of hemostasis Neutrophil extracellular traps in COVID-19 Lupus anticoagulant and abnormal coagulation tests in patients with Covid-19 Acute myocardial infarction after laboratoryconfirmed influenza infection Effects on coagulation and fibrinolysis induced by influenza in mice with a reduced capacity to generate activated protein C and a deficiency in plasminogen activator inhibitor type 1 Review: viral infections and mechanisms of thrombosis and bleeding The post-PE syndrome: a new concept for chronic complications of pulmonary embolism How I treat the postthrombotic syndrome Prospective evaluation of health-related quality of life in patients with deep venous thrombosis Quality of life, dyspnea, and functional exercise capacity following a first episode of pulmonary embolism: results of the ELOPE cohort study Determining the minimal clinically important difference for the PEmbQoL questionnaire, a measure of pulmonary embolism-specific quality of life The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs Post-thrombotic panic syndrome": a thematic analysis of the experience of venous thromboembolism Late outcomes of pulmonary embolism: the post-PE syndrome Deep-vein thrombosis in Europe -burden of illness in relationship to healthcare resource utilization and return to work Long-term psychosocial impact of venous thromboembolism: a qualitative study in the community Venous thrombosis risk associated with plasma hypofibrinolysis is explained by elevated plasma levels of TAFI and PAI-1 Decreased plasma fibrinolytic potential as a risk for venous and arterial thrombosis Mixed fibrinolytic phenotypes in decompensated cirrhosis and acute-on-chronic liver failure with hypofibrinolysis in those with complications and poor survival New functional assays to selectively quantify the activated protein C-and tissue factor pathway inhibitor-cofactor activities of protein S in plasma Role of factor XIA and plasma kallikrein in arterial and venous thrombosis Revisiting biomarker discovery by plasma proteomics Genes associated with venous thromboembolism in colorectal cancer patients Influenza virus damages the alveolar barrier by disrupting epithelial cell tight junctions Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction Activation of coagulation and tissue fibrin deposition in experimental influenza in ferrets Evaluating shortterm drug effects using a physician-specific prescribing preference as an instrumental variable Diagnostic management of acute deep vein thrombosis and pulmonary embolism Subcommittee on Control of Anticoagulation of the S, Standardization Committee of the International Society on T, Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients Tutorial in biostatistics: competing risks and multi-state models L1 penalized estimation in the Cox proportional hazards model The Post-COVID-19 Functional Status (PCFS) scale: a tool to measure functional status over time after COVID-19 Quality of life after pulmonary embolism: validation of the PEmb-QoL Questionnaire Pulmonary embolism Diagnosis of chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Sensitivity of a simple noninvasive screening algorithm for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism Essential aspects of the follow-up after acute pulmonary embolism: an illustrated review A simple non-invasive diagnostic algorithm for ruling out chronic thromboembolic pulmonary hypertension in patients after acute pulmonary embolism External validation of a simple non-invasive algorithm to rule out chronic thromboembolic pulmonary hypertension after acute pulmonary embolism To screen or not to screen for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT) Measuring functional limitations after venous thromboembolism: optimization of the Post-VTE Functional Status (PVFS) Scale The postthrombotic syndrome: evidence-based prevention, diagnosis, and treatment strategies: a scientific statement from the Individualised versus standard duration of elastic compression therapy for prevention of post-thrombotic syndrome (IDEAL DVT): a multicentre, randomised, single-blind, allocationconcealed, non-inferiority trial One versus two years of elastic compression stockings for prevention of post-thrombotic syndrome (OCTAVIA study): randomised controlled trial How to cite this article: Cannegieter SC, ten Cate H, van Caging the dragon: Research approach to COVID-19-related thrombosis haematologist Amphia hospital PhD-candidate Department of vascular medicine Prof. dr. S. Middeldorp, vascular medicine specialist nursing home specialist Drs Hunfeld, hospital pharmacist Prof. dr. E. C. M. van Gorp, infectious diseases specialist, Department Viroscience Prof. dr professor of comparative pathology, Department Viroscience Drs. T. Langerak, PhD-candidate, Department Viroscience Dr. M. N. Lauw, haematologist, Department Haematology Prof. dr. M. P. M. de Maat PhD-candidate Department Viroscience Drs PhD-candidate Department Viroscience Dr. B. Rockx, internist, Department Viroscience Dr. C. Rokx, infectious diseases specialist A. den Uil, Cardiologist-Intensivist Drs. C. Visser, PhD-candidate infectious diseases specialist Dr. M. ten Wolde Department of Medicine -Thrombosis and Haemostasis Drs. J. L. I, Burggraaf, PhD-candidate , Department of Clinical Epidemiology Prof. S. C. Cannegieter, clinical epidemiologist, Department of Medicine -Thrombosis and Hemostasis and Department of Department of Clinical Epidemiology Prof. dr. H. C. J. Eikenboom, haematologist/vascular medicine specialist PhD-candidate, Department of Medicine -Thrombosis and Hemostasis Dr. F. A. Klok, vascular medicine specialist Putter, statistician, Department of Biomedical Data Sciences Drs PhD-candidate, Department of Medicine -Thrombosis and Haemostasis Prof. dr. H .H. Versteeg, cellular biologist cellular biologist, associate professor, Department of Medicine -Thrombosis and Haemostasis Maasstad hospital den Hollander, infectious diseases specialist Ten Cate-Hoek, Clinical epidemiologist and medical director of thrombosis service Maastricht Prof internist subspecialized in geriatrics Dr. H. Spronk, biochemist executive board member CIRO and Professor in Rehabilitation Dr. K. Winckers, vascular medicine specialist Martini Hospital Dr. R. Hulst, hospital pharmacist Drs A infectious diseases specialist Noordwest Hospital Group Dr Onze Lieve Vrouwe Gasthuis hospital Prof. Dr. N. P. Juffermans infectious diseases specialist Drs Rijnstate hospital molecular and cellular biologist (and Amsterdam University Medical Centres) Department primary care vascular medicine specialist Wilhelmina hospital Assen Drs All authors contributed to the drafting of this manuscript and approved of the final submitted version.